Molecular Characterization of NF1 and Neurofibromatosis Type 1 Genotype-Phenotype Correlations in a Chinese Population

[1]  Alexander F. Wilson,et al.  Genetic Modifiers of Neurofibromatosis Type 1-Associated Café-au-Lait Macule Count Identified Using Multi-platform Analysis , 2014, PLoS genetics.

[2]  D. Milani,et al.  Is it time to change the neurofibromatosis 1 diagnostic criteria? , 2014, European journal of internal medicine.

[3]  X. Yang,et al.  Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing , 2014, International journal of molecular medicine.

[4]  D. Halley,et al.  A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands , 2014, Clinical genetics.

[5]  H. Saya,et al.  Multiple café au lait spots in familial patients with MAP2K2 mutation , 2014, American journal of medical genetics. Part A.

[6]  S. Pinson,et al.  Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion. , 2013, Journal of the American Academy of Dermatology.

[7]  S. Beri,et al.  Globus pallidus high-signal lesions: A predominant MRI finding in children with neurofibromatosis type 1 , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  E. Pasmant,et al.  Neurofibromatosis type 1: from genotype to phenotype , 2012, Journal of Medical Genetics.

[9]  K. Shah.  The diagnostic and clinical significance of café-au-lait macules. , 2010, Pediatric clinics of North America.

[10]  D. Cooper,et al.  Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions , 2010, Journal of Medical Genetics.

[11]  M. Sanson,et al.  NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype , 2010, Human mutation.

[12]  E. Zackai,et al.  Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. , 2009, JAMA.

[13]  J. Soulier,et al.  Technical Advance Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH , 2009 .

[14]  C. Lázaro,et al.  Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations , 2008, Human mutation.

[15]  B. Dallapiccola,et al.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification , 2007, Journal of Medical Genetics.

[16]  A. Krainer,et al.  Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice‐site disruption , 2007, Human mutation.

[17]  Robert Wall,et al.  Narrowing the gap. , 2006, AHIP Coverage.

[18]  E. Haan,et al.  An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. , 2007, American journal of human genetics.

[19]  W. Hwu,et al.  Identification of forty‐five novel and twenty‐three known NF1 mutations in Chinese patients with neurofibromatosis type 1 , 2006, Human mutation.

[20]  M. Upadhyaya,et al.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience , 2006, Familial Cancer.

[21]  W. Kaiser,et al.  Pediatric brain MRI in neurofibromatosis type I , 2005, European Radiology.

[22]  M. Dorschner,et al.  Genomic context of paralogous recombination hotspots mediating recurrent NF1 region microdeletion , 2004, Genes, chromosomes & cancer.

[23]  M. Kraut,et al.  Longitudinal evolution of unidentified bright objects in children with neurofibromatosis‐1 , 2004, American journal of medical genetics. Part A.

[24]  P. Tarpey,et al.  Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11–17 distinct from the GAP related domain , 2004, Journal of Medical Genetics.

[25]  Verena Wiest,et al.  Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: Toward a theory of genetic modifiers , 2003, Human mutation.

[26]  M. Dorschner,et al.  Recombination hotspot in NF1 microdeletion patients. , 2001, Human molecular genetics.

[27]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[28]  G Mortier,et al.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.

[29]  J. Szudek,et al.  Use of the National Institutes of Health Criteria for Diagnosis of Neurofibromatosis 1 in Children , 2000, Pediatrics.

[30]  P. Nürnberg,et al.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. , 2000, American journal of human genetics.

[31]  X. Estivill,et al.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. , 2000, Human molecular genetics.

[32]  L. Parreira.  [From the genotype to the phenotype]. , 1999, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[33]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.

[34]  E. Zackai,et al.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. , 1995, Radiology.

[35]  D. Easton,et al.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. , 1993, American journal of human genetics.

[36]  S. Huson,et al.  Ophthalmic manifestations of neurofibromatosis. , 1987, The British journal of ophthalmology.

[37]  M. Skolnick,et al.  The Genetic Aspects of Neurofibromatosis a , 1986, Annals of the New York Academy of Sciences.